Celgene Corp. Price Target Raised to $173.00 at Barclays (CELG)
Investment analysts at Barclays raised their price objective on shares of Celgene Corp. (NASDAQ:CELG) from $158.00 to $173.00 in a note issued to investors on Friday, AnalystRatingsNetwork.com reports. The firm currently has an “overweight” rating on the stock. Barclays’ target price suggests a potential upside of 9.52% from the company’s current price.
A number of other firms have also recently commented on CELG. Analysts at Jefferies Group raised their price target on shares of Celgene Corp. from $161.00 to $185.00 in a research note to investors on Friday. Separately, analysts at Brean Capital reiterated a “buy” rating on shares of Celgene Corp. in a research note to investors on Friday. They now have a $191.00 price target on the stock, up previously from $153.00. Finally, analysts at Guggenheim raised their price target on shares of Celgene Corp. from $152.00 to $176.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. Five research analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $150.26.
Celgene Corp. (NASDAQ:CELG) traded down 1.38% on Friday, hitting $155.78. 1,719,815 shares of the company’s stock traded hands. Celgene Corp. has a 1-year low of $70.42 and a 1-year high of $151.00. The stock’s 50-day moving average is $142.3 and its 200-day moving average is $125.4. The company has a market cap of $64.069 billion and a P/E ratio of 44.17.
Celgene Corp. (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 24th. The company reported $1.56 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.54 by $0.02. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter in the prior year, the company posted $1.29 earnings per share. The company’s quarterly revenue was up 18.0% on a year-over-year basis. Analysts expect that Celgene Corp. will post $5.98 EPS for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.